Every cell in your body runs on tiny power plants called mitochondria. 

They turn food into usable energy — like batteries powering your every move.

But as you age, these batteries begin to weaken, leak, or break down. 

The result? 

Fatigue, reduced endurance, slower recovery from exercise, and a higher risk of disease. 

Scientists call this mitochondrial dysfunction — but you can think of it as your body running on half-dead batteries.

⚡ How AmCELL Keeps Your Power On

✅ Quercetin and Gallic Acid act like electricians, sparking the growth of new mitochondria while recycling the broken ones.

✅ Ellagic Acid, through its superhero metabolite Urolithin A, works like a clean energy upgrade — boosting your cells’ fuel supply (ATP - Adenosine Triphosphate) and raising NAD⁺ levels, both vital for efficient energy production.

✅ C3G (Cyanidin 3-O-Galactoside) is the ultimate battery saver. 

Normally, an enzyme called CD38 acts like a background app constantly draining your energy. 

C3G slows CD38 down, preserving NAD⁺ and keeping your “battery” fully charged.

Together, these ingredients act like an elite repair team — clearing out faulty batteries, installing new ones, and ensuring every cell has the power it needs to thrive.

References:

Gao, J., Hu, J., Hu, D., & Yang, X. (2019). A role of gallic acid in oxidative damage diseases: A comprehensive review. Natural Product Communications, 14(8), 1934578X19874174.

Ho, C. L., Kao, N. J., Lin, C. I., Cross, T. W. L., & Lin, S. H. (2022). Quercetin increases mitochondrial biogenesis and reduces free radicals in neuronal SH-SY5Y cells. Nutrients, 14(16), 3310.

Liang, Z., Liang, H., Guo, Y., & Yang, D. (2021). Cyanidin 3-O-galactoside: A natural compound with multiple health benefits. International journal of molecular sciences, 22(5), 2261.

Liu, S., D’Amico, D., Shankland, E., Bhayana, S., Garcia, J. M., Aebischer, P., ... & Marcinek, D. J. (2022). Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA network open, 5(1), e2144279-e2144279.